Showing results (51-60 of 237) with videos related to
Sort By:
Pageof 24
Annals of Internal Medicine|October 17, 2022
Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based StudyGhadeer K Dawwas, Adam Cuker, Geoffrey D Barnes, et al.Thrombosis Research|December 7, 2024
Prevalence of discussions around left atrial appendage occlusion as a treatment option in patients on oral anticoagulation experiencing a major bleeding eventAmber Co, Chloe Kazaglis, Deborah DeCamillo, et al.Vascular Medicine (London, England)|November 10, 2023
Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative reviewSwathi Prakash, Adriana C Mares, Mateo Porres-Aguilar, et al.Journal of Thrombosis and Thrombolysis|January 30, 2023
Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillationDeborah DeCamillo, Brian Haymart, Xiaowen Kong, et al.The American Journal of Medicine|December 7, 2018
Periprocedural Antithrombotic Management from a Patient Perspective: A Qualitative AnalysisJennifer Acosta, Christopher Graves, Elizabeth Spranger, et al.Thrombosis Research|May 21, 2016
Use of decision aids for shared decision making in venous thromboembolism: A systematic reviewGeoffrey D Barnes, Brett Izzo, Marisa L Conte, et al.Implementation Science Communications|June 29, 2023
Dynamic interplay between available resources and implementation climate across phases of implementation: a qualitative study of a VA national population health toolYing-Jen Lin, Allison Ranusch, F Jacob Seagull, et al.Journal of Vascular Surgery. Venous and Lymphatic Disorders|September 11, 2020
Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infectionAndrea T Obi, Geoffrey D Barnes, Lena M Napolitano, et al.The American Journal of Cardiology|November 11, 2015
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationBrian M Salata, David W Hutton, Deborah A Levine, et al.The Annals of Pharmacotherapy|August 14, 2018
Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and DiltiazemJenna W Bartlett, Elizabeth Renner, Erin Mouland, et al.Pageof 24